Sign In

Analgesics in
USA

Country Report

US$990
Add to cart

Executive Summary

Oct 2019
PROSPECTS
Ageing population and chronic diseases help push sales in analgesics

Although the elderly population (defined as aged 65 or above) is growing worldwide, a 2018 report from the US Census Bureau drew renewed attention to the elderly population in the US especially: by the year 2035, adults aged 65 or older will outnumber children for the first time in US history. This report came at a tumultuous time for US politics, in which the ageing of America was often a topic of political conversation, especially when it came to healthcare reform and the long-term future of entitlement programmes such as Medicare and Social Security.

Wary of side-effects, consumers increasingly turning to topical options

Although sales of systemic analgesics continue to significantly eclipse those of topical analgesics/anaesthetic, the latter has continued to grow at a significant pace between 2018 and 2019. The primary appeal of topical analgesics among consumers comes from the limited side-effects associated with their use: most are based on natural, botanical ingredients with which consumers are familiar and trust to address their symptoms without causing any physical damage.

Natural alternatives such as CBD help slow growth looking ahead

Cannabidiol (CBD) is rapidly gaining popularity as a completely natural alternative to pain management. Consumers looking to manage chronic pain without chemicals are increasingly looking to CBD oil in capsules, oils, and creams/gels, in some cases moving away even from natural remedies such as menthol-based topical analgesics.

COMPETITIVE LANDSCAPE
Advil maintains its lead in systemic analgesics despite sales decline

Three of the four major systemic analgesic brands (Advil (Pfizer), Aleve (Bayer AG) and Bayer Aspirin (Bayer AG)) saw a decline between 2018 and 2019 as consumers increasingly look for alternative forms of pain management that do not involve ingesting a chemical - this trend is particularly noteworthy this year as even though other treatment options have been popular for several years, they had not yet directly affected the sales of the powerhouse systemic brands until now. In contrast, Johnson & Johnson’s Tylenol registered modest but positive growth, indicating the brand’s resistance to the shift to naturals and ongoing popularity with consumers, particularly when it comes to Tylenol’s paediatric and infant offerings, which benefit from a strong degree of trust among consumers.

Competition remains fierce in topicals with Icy Hot (Sanofi) under threat

Topical analgesics continued their rise in 2019, with Icy Hot (Sanofi) still in the number one spot despite threats from second- and third-ranked brands Salonpas (Hisamitsu) and Biofreeze (Hygienic Corp), respectively. In terms of highest growth, internet sensation Penetrex (Biomax Health Products) registered double-digit growth due to the brand’s cult-like following on Amazon.

Changing consumer preferences leads to slowing growth over forecast period

Pain management remains a key concern for US consumers, particularly the elderly and those suffering from chronic disease. That said, as more consumers look for ways to address their pain with holistic and/or natural remedies, they will slowly continue to move away from traditional methods of pain management toward products that are non-invasive, with fewer side-effects, and that fit into an overall picture of what natural health looks like.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports
Frequently asked questions Our Definitions

Analgesics in the US

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in USA with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Analgesics industry in USA, our research will save you time and money while empowering you to make informed, profitable decisions.

The Analgesics in USA market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Analgesics in USA?
  • What are the major brands in USA?
  • Are combination products with acetaminophen still popular?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Analgesics in the US - Category analysis

HEADLINES

PROSPECTS

Ageing population and chronic diseases help push sales in analgesics
Wary of side-effects, consumers increasingly turning to topical options
Natural alternatives such as CBD help slow growth looking ahead

COMPETITIVE LANDSCAPE

Advil maintains its lead in systemic analgesics despite sales decline
Competition remains fierce in topicals with Icy Hot (Sanofi) under threat
Changing consumer preferences leads to slowing growth over forecast period

CATEGORY DATA

Table 1 Sales of Analgesics by Category: Value 2014-2019
Table 2 Sales of Analgesics by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Analgesics: % Value 2015-2019
Table 4 LBN Brand Shares of Analgesics: % Value 2016-2019
Table 5 Forecast Sales of Analgesics by Category: Value 2019-2024
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2019-2024

Consumer Health in the US - Industry Overview

EXECUTIVE SUMMARY

Consumer demand for naturals stimulates both growth and competition
Preventative health remains a key focus
Key brands in OTC maintain their dominance
New positionings drive growth in vitamins and dietary supplements (VDS)
Continued growth expected over the forecast period, with high variations across categories

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format: % Value 2014-2019
Table 15 Distribution of Consumer Health by Format and Category: % Value 2019
Table 16 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventative medicine
Switches

DEFINITIONS

SOURCES

Summary 1 Research Sources